Research Article|Articles in Press, 103686

Reduction of anti-A and anti-B isoagglutinin titers of group O whole blood units employing an ABO antibody immune adsorption column



      Massive hemorrhage is a leading cause of death from trauma. There is growing interest in group O whole blood transfusions to mitigate coagulopathy and hemorrhagic shock. Insufficient availability of low-titer group O whole blood is a barrier to routine use. We tested the efficacy of the Glycosorb® ABO immunoadsorption column to reduce anti-A/B titers in group O whole blood.


      Six group O whole blood units were collected from healthy volunteers, and centrifuged to separate platelet poor plasma. Platelet-poor plasma was filtered through a Glycosorb® ABO antibody immunoabsorption column, then reconstituted to prepare post-filtration whole blood. Anti-A/B titers, CBC, free hemoglobin, and thromboelastography (TEG) assays were performed on pre-and post-filtration whole blood.


      Mean( ± SEM) anti-A (224 ± 65 pre vs 13 ± 4 post) and anti-B (138 ± 38 pre vs 11 ± 4 post) titers were significantly reduced (p = 0.004) in post-filtration whole blood. No significant changes were detected in CBC, free hemoglobin, and TEG parameters on day 0. Free hemoglobin increased throughout storage (48 mg/dl ± 24 Day 0 vs 73 ± 35 Day 7 vs 96 ± 44 Day 14; p = 0.14).


      The Glycosorb® ABO column can significantly reduce anti-A/B isoagglutinin titers of group O whole blood units. Glycosorb® ABO could be employed to provide whole blood with lower risk of hemolysis and other consequences of infusing ABO incompatible plasma. Preparation of group O whole blood with substantially reduced anti-A/B would also increase the supply of low-titer group O whole blood for transfusion.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Transfusion and Apheresis Science
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Spinella P.C.
        • Gurney J.
        • Yazer M.H.
        Low titer group O whole blood for prehospital hemorrhagic shock: it is an offer we cannot refuse.
        Transfusion. 2019; 59: 2177-2179
        • McRae H.L.
        • Kara F.
        • Milito C.
        • Cahill C.
        • Blumberg N.
        • Refaai M.A.
        Whole blood haemostatic function throughout a 28-day cold storage period: an in vitro study.
        Vox Sang. 2021; 116: 190-196
        • Yazer M.H.
        • Spinella P.C.
        An international survey on the use of low titer group O whole blood for the resuscitation of civilian trauma patients in 2020.
        Transfusion. 2020; 60: S176-S179
        • Sperry J.L.
        Prehosptial low titer group O whole blood is feasible and safe: results of a prospective randomized pilot trial.
        J Trauma Acute Care Surg. 2022;
        • Refaai M.A.
        • Cahill C.
        • Masel D.
        • Schmidt A.E.
        • Heal J.M.
        • Kirkley S.A.
        • et al.
        Is it time to reconsider the concepts of "Universal Donor" and "ABO Compatible" transfusions?.
        Anesth Analg. 2018; 126: 2135-2138
        • Hazelton J.P.
        • Ssentongo A.E.
        • Oh J.S.
        • Ssentongo P.
        • Seamon M.J.
        • Byrne J.P.
        • Armento I.G.
        • et al.
        Use of cold-stored whole blood is associated with improved mortality in hemostatic resuscitation of major bleeding: a multicenter study.
        Ann Surg. 2022; 276: 579-588
        • Shea S.M.
        • Staudt A.M.
        • Thomas K.A.
        • Schuerer D.
        • Mielke J.E.
        • Folkerts D.
        • et al.
        The use of low-titer group O whole blood is independently associated with improved survival compared to component therapy in adults with severe traumatic hemorrhage.
        Transfusion. 2020; 60: S2-S9
        • Magid-Bernstein J.
        • Beaman C.B.
        • Carvalho-Poyraz F.
        • Boehme A.
        • Hod E.A.
        • Francis R.O.
        • et al.
        Impacts of ABO-incompatible platelet transfusions on platelet recovery and outcomes after intracerebral hemorrhage.
        Blood. 2021; 137: 2699-2703
        • Shanwell A.
        • Andersson T.M.L.
        • Rostgaard K.
        • Edgren G.
        • Hjalgrim H.
        • Norda R.
        • et al.
        Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma.
        Vox Sang. 2009; 96 ( 316-323
        • Inaba K.
        • Branco B.C.
        • Rhee P.
        • Holcomb J.B.
        • Blackbourne L.H.
        • Shulman I.
        • et al.
        Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients.
        Arch Surg. 2010; 145 (In eng). DOI: 145/9/899 [pii] 10.1001/archsurg.2010.175: 899-906
        • Refaai M.A.
        • Fialkow L.B.
        • Heal J.M.
        • Henrichs K.F.
        • Spinelli S.L.
        • Phipps R.P.
        • et al.
        An association of ABO non-identical platelet and cryoprecipitate transfusions with altered red cell transfusion needs in surgical patients..
        Vox Sang. 2011; 101: 55-60